• Select your website

2014 Laureate in Portugal

IBI-Cardiorotors, by Bruno Gil

A non-invasive imaging system for the diagnosis of atrial fibrillation

Bruno Gil with Célia Reis, Managing Director at Altran Portugal

In Portugal, the jury awarded the project IBI-Cardiorotors as the 2014 laureate. IBI-Cardiorotors is a non-invasive diagnostic tool used in analysing the mechanisms underlying the appearance and continued presence of atrial fibrillation (AF), thus helping to determine the best strategy for treatment by catheter ablation.

A chest vest equiped by electric and magnetic field sensors is used to capture electrical information, either in outpatient environment (telemetry) or surgery. These sensors can build a cardiac 4D image based on impedance tomography maps, eliminating the need for 3D-Computered Tomography or MRI scans.

Of the four finalists – at this stage all projects of high quality in the telemedicine field – the Jury of the Altran Foundation in Portugal chose IBICardioRotors, precisely due to the high importance of the project to improve health care for patients, which becomes possible through technological innovation. We understand the importance of these awards to recognize R&D work and the need to provide support from companies, so that their projects can grow further and develop itself. For this exact reason, the winning team will count with our collaboration, through customized support from our team. Célia Reis, Managing Director at Altran Portugal
Bruno Gil, from IBICardiorotors

Atrial fibrillation (AF), the most common abnormal heart rhythm

AF is the most frequent cardiac arrhythmia encountered in clinical practice, and that which leads to the highest number of hospitalisations. Its occurrence determines the deterioration of the atria’s contractile function, irregular ventricular response, thus reducing cardiac performance and functional capacity, which has a negative impact on quality of life, morbidity and mortality. AF concerns nearly 1% of the world’s population and increases significantly with age, affecting 4% of people over age 60, 10% of people over age 80, and more than 17% of people over age 85. AF is also associated with structural heart disease, but can occur without any evidence of heart disease in one-third of cases, and in nearly half of cases involving young patients.